AcouSort: Scientific progress with AcouWash enables new method for cancer treatment monitoring
As previously reported, NIH purchased the first AcouWash prototype in 2017 and has since used the system for an important cell wash step in their development of a new method for cancer treatment monitoring. The NIH researchers have conducted a study comparing AcouWash-based cell wash to a conventional centrifugation-based protocol. The results have now been published in Scientific Reports, a journal from the Nature Portfolio, successfully validating the AcouWash for the intended application. According to the authors of the publication, the study shows that acoustophoresis cell washing can be used in the design of an automated benchtop, GMP-qualified cell radiolabeling device. This is an important step toward a future integration of AcouSort’s cell washing technology specifically designed as an automated clinical benchtop system for cancer treatment applications.
– We are very pleased that the US National Cancer Institute at NIH, which is an important reference customer, has produced such positive results in their study. This also confirms that our strategy of using benchtop systems as platforms for evaluating the technology, says AcouSort’s CEO Torsten Freltoft.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.